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Abstract This cross-sectional study aimed to evaluate IVF/intracytoplasmic sperm injection (ICSI) outcomes in different polycystic
ovary syndrome (PCOS) phenotypes (A, B, C and D) compared with a control group and the predictive values of serum anti-Müllerian
hormone (AMH) in PCOS phenotypes for main outcomes. This study evaluated 386 PCOS women and 350 patients with male factor
infertility. Women with phenotypes A and C had signiﬁcantly higher concentrations of AMH than those with phenotype B (P < 0.001).
Clinical pregnancy rate (CPR) in the phenotype D group (53.3%) was higher than other groups (32.5%, 26.4% and 36.8%, respectively,
in phenotypes A, B and C), but not to a signiﬁcant level. Multivariable regression analysis, after adjusting for women’s age and body
mass index, revealed that PCOS phenotypes A and B were associated with a decreased CPR compared with the control group (odds
ratio [OR]: 0.46, conﬁdence interval [CI]: 0.26–0.8, P = 0.007 and OR: 0.34, CI: 0.18–0.62, P = 0.001, respectively). It seems a com-
bination of hyperandrogenism and chronic anovulation is associated with a negative impact on the CPR in these patients. These results
demonstrated that AMH concentration is related to PCO morphology but not predictive for CPR and live birth rate.
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Introduction
Polycystic ovary syndrome (PCOS) is a common cause of female
infertility and affects 15–25% of women, based on the Rot-
terdam criteria (Livadas and Diamanti-Kandarakis, 2013). PCOS
constitutes a continuous spectrum of symptoms starting from
the early prepubertal years and continuing after meno-
pause. Phenotypes are the clinical features resulting from the
interaction between heredity and environment in a disease
or syndrome (Moran et al., 2012). The phenotypic expres-
sion of PCOS varies through time and depends on several in-
ternal (e.g. genetic inﬂuence (Cui et al., 2015), ovarian/
adrenal steroidogenesis and insulin resistance) and external
(e.g. quality and quantity of diet, exercise and lifestyle) factors
(Livadas and Diamanti-Kandarakis, 2013). Moreover, the emer-
gence of new deﬁnitions with the use of ovarian morphol-
ogy as well as chronic anovulation and hyperandrogenism, as
diagnostic criteria, has developed the phenotypic variety of
PCOS (Livadas and Diamanti-Kandarakis, 2013). To our knowl-
edge, very few studies have evaluated the outcomes of as-
sisted reproductive technology (ART) in the different
phenotypes of PCOS women (Palomba et al., 2010).
Recently, anti-Müllerian hormone (AMH) has been consid-
ered a diagnostic or even prognostic marker of PCOS (Karkanaki
et al., 2011). Tal et al. (2014) in a recent study stated that
the concentration of serum AMH might be related to the se-
verity of PCOS and correlate with its clinical diagnostic hall-
marks (i.e. hyperandrogenism, oligo/anovulation and polycystic
ovary morphology [PCOM]). Pregnancy rates are likely to de-
crease with the exacerbation of PCOS (Sahmay et al., 2013).
Although some studies have suggested a reverse relation-
ship between the AMH concentration and pregnancy rates (Xi
et al., 2012), some others have found a positive relation-
ship between the AMH concentration, embryo quality and clini-
cal pregnancy rates (Tal et al., 2014).
On the other hand, an elevated concentration of basal LH
due to enhanced pulsatile gonadotrophin-releasing hormone
(GnRH) release is one of the hallmark endocrinological dis-
turbances in PCOS women. Increased LH concentrations are
observed in about 70% of PCOS patients with elevated LH pulse
amplitude and an increased LH pulse frequency, which causes
a two- to threefold elevation in serum LH concentrations versus
FSH concentrations (Piouka et al., 2009). The potential impact
of a high concentration of LH, and speciﬁcally a high LH/
FSH ratio on human reproduction, is still under debate. Some
studies reported negative impacts of high LH or LH/FSH ratio
on the number of follicles as well as the number and matu-
rity of oocytes (Tarlatzis et al., 1995), embryo quality and clini-
cal pregnancy rates (CPR) (Wiser et al., 2013); however, other
studies could not ﬁnd any adverse effects (Geng et al., 2013;
Mendoza et al, 2002). Elsewhere, Brodin et al., (2009) con-
cluded that a low FSH concentration combined with high LH
probably shows a well-preserved ovarian reserve and is as-
sociated with high pregnancy rates in IVF/ICSI cycles.
PCOS has its unique properties such as increased antral fol-
licle count, serum AMH and LH/FSH ratio. Therefore, the
prediction of clinical pregnancy in women with PCOS is more
challenging than non-PCOS women (Sahmay et al., 2013). The
present study was designed to evaluate: (i) ART outcomes in
different PCOS phenotypes compared with the control group;
and (ii) the predictive values of serum AMH and LH/FSH ratio
in PCOS phenotypes for ART outcomes.
Materials and methods
Patients
This cross-sectional study was performed in the Royan Insti-
tute from June 2012 to January 2014. The Institutional Review
Board and Ethics Committee of Royan Institute approved the
study protocol on 15 June 2015 (reference number EC90/
1010). The study was performed in accordance with the Hel-
sinki Declaration and adhered to the guidelines of the
Committee of Publication Ethics. All the participants signed
the informed consent. All infertile women diagnosed with PCOS
who underwent the ﬁrst IVF/ICSI cycle were enrolled during
the study period. Other causes of infertility including severe
endometriosis, hydrosalpinx, uterine factor, severemale factor
(oligo-tetrato-asthenozoospermia), and age factor (≥40) or di-
minished ovarian reserve (AMH < 1 ng/ml, FSH > 12 IU/l) were
excluded. Only patients with mild/moderate male factor and/
or tubal factor infertility were included. Meanwhile smokers
and diabetic patients were excluded from the study.
PCOS cases were diagnosed based on the Rotterdam cri-
teria (2004), and the presence of at least two of the follow-
ing criteria: menstrual irregularity (cycle length <26 days or
>35 days or variation between consecutive cycles of >10 days);
clinical (presence of hirsutism evaluated by a Ferriman-
Gallwey score >8, severe acne and alopecia) or biochemical
(total testosterone concentration >0.5 ng/ml and/or free tes-
tosterone >3.5 pg/ml) hyperandrogenism; or ultrasound evi-
dence of polycystic ovaries. Hirsutism was assessed according
to the Ferriman-Gallwey-score and examination of nine body
areas for coarse terminal hair, including upper lip, chin and
chest, upper and lower areas of the abdomen, thighs and upper
arms. In each part, the severity of hirsutism was graded from
1 to 4 and the participants with the total score of 8 and above
considered as having hirsutism. PCOM was deﬁned as the pres-
ence of 12 or more ovarian cysts with 2–10 mm diameter per
ovary and/or ovarian volume ≥10 cm3. Vaginal ultrasound was
performed by an ultrasound specialist and radiologist using
an Aloka α-10 with a transvaginal 6–7.5 MHz probe (Medison
Co., Japan). Patients with other differential diagnoses, in-
cluding hyperprolactinaemia, thyroid dysfunction, hypotha-
lamic amenorrhoea, Cushing’s syndrome and ovarian failure,
were detected via hormonal tests and excluded from the study.
PCOS patients were categorized to four phenotype groups ac-
cording to the Rotterdam criteria: (i) phenotype A: the co-
existence of hyperandrogenism, chronic anovulation and
polycystic ovaries (HA+AO+PCO); (ii) phenotype B: chronic an-
ovulation and hyperandrogenism without the polycystic ovaries
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(AO+HA); (iii) phenotype C: hyperandrogenism and polycys-
tic ovaries (HA+PCO); and (iv) phenotype D: polycystic ovaries
coexisting with anovulatory cycles (AO+PCO).
Normal women (who were diagnosed as male factor in-
fertility) who underwent ﬁrst IVF/ICSI cycle during the study
period were considered as the control group. Male factor in-
fertility is generally determined by two or more abnormal
semen analyses, according to the World Health Organiza-
tion (WHO) criteria, 2010: total sperm count <39 × 106/ml and/
or progressive motility <32% and/or normal morphology <4%.
Investigations
All the hormonal assays were performed in the Royan Insti-
tute laboratory. Blood samples were collected for the
assessment of basal serum LH, FSH, AMH and fasting blood
sugar (FBS) concentrations on days 2–3 of the menstrual
cycle in all the women. Further evaluation in PCOS women
was performed by measurement of total and free testoster-
one concentrations. The serum AMH concentration was
measured using a commercial enzyme-linked immunosorbent
assay (ELISA) kit (AMH Gen II ELISA; Beckman Coulter, Inc.,
USA). To synchronize timing, by a specialist who performed
the AMH measurements, part of the serum samples of all
studied patients were collected and stored frozen at −80°C
until analysis. Finally, all AMH measurements were carried
out at the end of sampling. Laboratory specialists prepared
one part of each calibrator, control or test samples, respec-
tively, with ﬁve parts of AMH Gen II assay buffer; in this
preparation method, no dilution factor is required. Accord-
ing to kit instruction, any sample that read higher than the
highest calibrator was diluted with sample dilutent, and the
diluted sample was tested again. The intra-assay and inter-
assay coefﬁcients of variation were 5.4% and 5.6%,
respectively. The serum concentrations of FSH and LH were
measured using electro-chemiluminescence immunoassay kits
(ECLIA kits, Roche Diagnostics GmbH, Germany) on an Elecsys
immunoassay analyser. Total serum testosterone and free
testosterone concentrations in the patients with irregular
menses and/or polycystic ovaries were assessed by the ELISA
kits (Monobind Inc., USA) and concentrations are given in
ng/ml and pg/ml, respectively. Fasting blood sugar (FBS;
mg/dl) was measured by using means of enzymatic colorim-
etry (Pars Azmun Co. Tehran, Iran).
Treatment
Based on the physician’s decision, one of the two standard
protocols of long agonist or antagonist (Stimpfel et al., 2015)
was used for controlled ovarian stimulation (COH) with re-
combinant FSH (75–150 IU) considering the antral follicle count
(AFC) and the women’s age. Either IVF/ICSI or ICSI was con-
ducted in accordance with the clinical indication. Fertiliza-
tion rate was deﬁned as the number of fertilized embryos
obtained per all injected and/ or inseminated oocytes. De-
pending on the women’s age and the quality of the embryos,
two or three embryos were transferred on day 3 after oocyte
retrieval. The quality of the embryos was graded as A, B, C
or D (A being the best and D being the worst) based on the
number of cells, degree of fragmentation and regularity.
Outcomes
All the cycle outcomes, namely freeze-all-embryos cases, fer-
tilization, implantation, clinical pregnancy and miscarriage
rates, as well as the live birth rate (LBR) were recorded. Im-
plantation rate was deﬁned as the number of observed in-
trauterine gestational sacs divided by the number of
transferred embryos. A clinical pregnancy was considered as
ultrasonographic visualization of an intrauterine gestational
sac with fetal heartbeat. A spontaneous miscarriage was con-
sidered as a clinical pregnancy lost before 20 weeks’ gesta-
tion. In PCOS patients the LH/FSH ratio was evaluated in two
subgroups (LH/FSH <2.5 and LH/FSH ≥2.5), and the cut-off
point was considered at 10 IU/ml for basal serum LH.
Statistical analysis
The study population’s demographic factors, IVF/ICSI cycle-
speciﬁc parameters and pregnancy outcomes were com-
pared between the four PCOS phenotypes using the
chi-squared test for the categorical variables and the one-
way analysis of variance test (with the Tukey post-hoc test)
for the continuous variables, when the data had a normal dis-
tribution, and the Kruskal-Wallis test in the non-normal cases.
In order to detect the predictive variables of clinical preg-
nancy rate (CPR) and LBR, the study used a multivariable lo-
gistic regression analysis in a backward manner in PCOS
phenotypes and control group separately and then gener-
ally. The covariate variables in the PCOS group included:
women’s age and body mass index (BMI), serum AMH con-
centration, LH/FSH ratio, serum free testosterone and FBS
concentrations, stimulation protocol, number of gonadotro-
phins ampoules, number of retrieved oocytes and number and
quality of the transferred embryos. In the male factor (control
group), covariate variables included: women’s age and BMI,
serum AMH concentration, infertility type, stimulation pro-
tocol, number of gonadotrophins ampoules, number of re-
trieved oocytes and number and quality of the transferred
embryos that were entered in the multivariable logistic re-
gression model. Finally, for multivariable logistic regression
analysis adjusted for women’s age and BMI in the whole study
population (n = 736), important variables such as study groups,
serum AMH concentration, LH/FSH ratio, number of re-
trieved oocytes, quality of transferred embryos, number of
gonadotrophins ampoules and stimulation protocol were
entered into the model.
It was estimated by using the NCSS software (Number
Cruncher Statistical System software package 2007, Kaysville,
UT, USA) that a sample size of more than 80 subjects in each
group would support us to demonstrate a difference in AMH
concentrations between subjects and controls of 1 ng/ml with
a power of 80% and a type I error of 0.05. It was also calcu-
lated that a sample size of 350 subjects in each group would
allow us to demonstrate 15% difference in CPR between sub-
jects and controls with a power of 80% and a type I error of
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0.05. The data were analysed using the Statistical Package
for Social Sciences (SPSS) version 20.0 (IBM Corp., USA). Sta-
tistical signiﬁcance level was considered as a P-value <0.05.
Results
In total, 386 cases with a PCOS diagnosis and 350 male factor
patients were enrolled during the study period. Table 1 shows
the patients’ characteristics among four PCOS phenotypes and
control group. The results showed that the study groups were
comparable in terms of female age at cycle initiation, age at
menarche, infertility type and duration of infertility. As ex-
pected, PCOS subgroups compared with the control group had
signiﬁcant differences in terms of BMI, serum FBS, FSH and
LH concentrations. Also, AFC and serum AMH concentra-
tions were signiﬁcantly different among study groups (P <
0.001). The proportions of the cases with basal LH >10 IU/l
and LH/FSH ratio ≥2.5 were similar in the different pheno-
type groups. There were also signiﬁcant differences between
the phenotype groups concerning the AMH concentration
insofar as phenotypes A and C had signiﬁcantly higher con-
centrations of the serum AMH than phenotype B (P = 0.003
and P = 0.01, respectively) (Table 1).
Table 2 shows IVF/ICSI cycle outcomes among four PCOS
phenotypes and the control group. There were no statisti-
cally signiﬁcant differences among PCOS phenotypes groups
in terms of stimulation duration, the total number of re-
trieved and metaphase II (MII) oocytes, the number and quality
of the transferred embryos and endometrial thickness on the
embryo transfer day. The proportions of the antagonist cycles
and the freeze-all cases in the phenotype B and control group
were lower than those in the other phenotype groups (P <
0.001). Moreover, the phenotype B group had a tendency to
have a higher number of used gonadotrophin ampoules than
the other PCOS groups; although the difference was not sta-
tistically signiﬁcant. The control group was signiﬁcantly dif-
ferent in terms of stimulation protocol, number of follicles
≥12 mm, total number of embryos and the freeze-all-
embryos cases compared with the four PCOS phenotypes (all
P < 0.001).
Table 1 Comparison of the study population’s characteristics among four PCOS phenotypes and control group.
Phenotype A Phenotype B Phenotype C Phenotype D Control
(Male factor)
P-value*
(n = 168) (n = 103) (n = 83) (n = 32) (n = 350)
Women’s age (years) (mean ± SD) 32.1 ± 4.7 32.2 ± 5.3 30.8 ± 4.6 32.4 ± 4.4 31.0 ± 5.2 NS
Menarche age (years)
(mean ± SD)
13.2 ± 1.5 13.4 ± 1.6 13.5 ± 1.7 12.8 ± 1.3 13.1 ± 1.5 NS
BMI (kg/m2) (mean ± SD) 27.6 ± 3.9e 27.5 ± 4.9e 27.1 ± 3.9e 26.4 ± 4.0 25.2 ± 4.0 <0.001
FSH (IU/l) (mean ± SD) 5.8 ± 1.9e 5.9 ± 2.6e 5.8 ± 2.2e 6.2 ± 2.7 6.9 ± 3.1 <0.001
LH (IU/l) (mean ± SD) 8.4 ± 5.7e 6.9 ± 4.8e 7.5 ± 5.4e 7.7 ± 6.4e 4.9 ± 3.2 <0.001
AMH (ng/ml) (mean ± SD) 6.8 ± 2.8b,e 5.1 ± 3.1a,c,e 6.3 ± 2.9b,e 5.8 ± 2.4e 2.3 ± 1.8 <0.001
FBS (mg/dl) (mean ± SD) 89 ± 12.6b,e 88.0 ± 10.2a,c,d 91.0 ± 10.5b,e 91.1 ± 8.9b,e 86.7 ± 6.4 <0.001
Total testosterone concentration
(ng/ml) (mean ± SD)
1.3 ± 0.6c,d 1.1 ± 0.5c,d 1.0 ± 0.3a,d 0.3 ± 0.1a,b,c –# <0.001
Free testosterone concentration
(pg/ml) (mean ± SD)
4.1 ± 0.9c,d 3.9 ± 0.8c,d 3.7 ± 0.4a,b,c 1.8 ± 0.7a,b,c –# <0.001
Basal LH >10 IU/l, n (%) 49 (29.2) 23 (22.3) 21 (25.3) 9 (28.1) 22 (6.3) <0.001
LH/FSH ratio ≥2.5, n (%) 25 (14.9) 18 (17.5) 10 (12.0) 4 (12.5) 9 (2.6) <0.001
AFC (mean ± SD) 35.4 ± 4.8b,d,e 20.0 ± 1.8a,c,d,e 35.1 ± 4.6b,d,e 33.2 ± 3.9a,b,c,e 11.2 ± 2.4 <0.001
Type of infertility, n (%) NS
Primary 146 (87.4) 90 (87.4) 75 (90.4) 28 (87.5) 326 (93.1)
Secondary 21 (12.6) 13 (12.6) 8 (9.6) 4 (12.5) 24 (6.9)
Cause of infertility, n (%) NS
PCOS 98 (58.7) 62 (60.2) 46 (55.4) 19 (59.4) –
PCOS and male factor 69 (41.3) 41 (39.8) 37 (44.6) 13 (40.6) –
Infertility duration (years) 6.8 ± 2.9 6.9 ± 2.8 6.2 ± 2.9 6.2 ± 2.5 6.8 ± 3.8 NS
AFC = antral follicle count; BMI = body mass index; FBS = fasting blood sugar; NS = not statistically signiﬁcant; PCOS = polycystic ovary syndrome.
aSigniﬁcantly different from phenotype A (the coexistence of hyperandrogenism (HA), chronic anovulation (AO), and polycystic ovaries).
bSigniﬁcantly different from phenotype B (HA and AO without the polycystic ovaries).
cSigniﬁcantly different from phenotype C (HA and polycystic ovaries).
dSigniﬁcantly different from phenotype D (AO and polycystic ovaries).
eSigniﬁcantly different from control group.
*All P-values for quantitative variables were determined by post-hoc analysis (Tukey).
#Serum testosterone levels were measured in patients with irregular menses or clinical signs of hyperandrogenism and/or PCOS morphology
in sonography.
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Although fertilization rate was signiﬁcantly lower in the
control group (P < 0.001), the implantation rate and CPR was
signiﬁcantly higher thanPCOSphenotypesA,BandC (P<0.001).
However, miscarriage and LBR were not signiﬁcantly differ-
ent among groups. A tendency to higher implantation rate,
CPR and LBR was observed in patients with phenotype D com-
pared with the other PCOS phenotypes; however, these dif-
ferences did not reach signiﬁcant levels (Table 2).
The study compared the main outcomes between two
groups based on the presence of the PCOM by vaginal ultra-
sonography (Table 3). The results showed that women with
PCOM had signiﬁcantly higher concentrations of serum AMH
(P = 0.001) and there was a non-signiﬁcant trend towards
higher LH values in the PCOM group. The rate of freeze-all-
embryos was greater in PCOS women with the presence of the
PCOM in ultrasonography (P = 0.001). No relationship between
Table 2 Comparison of cycle outcomes among four PCOS phenotypes and control group.
Phenotype A Phenotype B Phenotype C Phenotype D Control group
(Male factor)
*P-value
(n = 168) (n = 103) (n = 83) (n = 32) (n = 350)
Stimulation protocol, n (%)
Long agonist 79 (47) e 79 (76.7)a,c,d,e 39 (47)e 17 (53.1)e 318 (90.9) <0.001
Antagonist 89 (53) 24 (23.3) 44 (53) 15 (46.9) 32 (9.1)
No. of gonadotropin ampoules
(mean ± SD)
22.1 ± 11.8e 25.3 ± 9.8 22.7 ± 7.3e 23.3 ± 7.2 26.8 ± 9.8 <0.001
Stimulation
duration (days) (mean ± SD)
10.1 ± 2.3 10.4 ± 2.1 10.3 ± 1.9 10.3 ± 2.1 10.8 ± 2.1 NS
No. of follicles ≥
12 mm (mean ± SD)
15.6 ± 11.0b,e 12.4 ± 5.0e 14.1 ± 7.5e 12.7 ± 8.7a,e 12.1 ± 6.5 <0.001
No. of retrieved
oocytes (mean ± SD)
11.3 ± 6.7 11.0 ± 7.3 11.2 ± 6.3 11.2 ± 7.1 10.1 ± 5.5 NS
No. of MII oocytes (mean ± SD) 9.2 ± 4.7 9.2 ± 5.9 9.2 ± 5.1 9.5 ± 6.2 8.6 ± 5.4 NS
Total no. of
embryos (mean ± SD)
7.7 ± 4.5e 7.2 ± 4.6e 7.0 ± 4.6e 7.6 ± 4.4e 5.5 ± 4.1 <0.001
No. of transferred
embryos (mean ± SD)
2.2 ± 0. 6 2.3 ± ± 0.7 2.1 ± 0.6 2.2 ± 0.5 2.3 ± 0.7 NS
Quality of transferred embryos,
n (%)
NS
Good (quality of all transferred
embryos was A, B, and AB)
60 (77.9) 55 (76.4) 25 (65.8) 10 (66.7) 176 (63.5)
Fair (half of transferred
embryos were good
quality (AC and BC)
12 (15.6) 15 (20.8) 10 (26.3) 4 (26.7) 76 (27.4)
Poor (quality of all transferred
embryos was poor (C and CD)
5 (6.5) 2 (2.8) 3 (7.9) 1 (6.7) 25 (9.0)
Endometrial thickness on ET day
(mean ± SD)
9.9 ± 1.3 9.8 ± ± 1.6 9.6 ± 1.6 9.9 ± 1.2 9.8 ± 1.7 NS
Freeze-all-embryos 83 (49.4)e 28 (27.2)a,c,d,e 40 (48.2)e 16 (50.0)e 40 (11.4) <0.001
Cancellation rate (no oocyte, no
embryo and abnormal
endometrial thickness)
8 (4.8) 3 (2.9) 5 (6.0) 1 (3.1) 35 (10.0) NS
Fertilization rate (mean ± SD) 0.75 ± 0.22e 0.74 ± 0.23e 0.77 ± 0.21e 0.76 ± 0.22e 0.64 ± 0.26 <0.001
Implantation rate (mean ± SD) 0.19 ± 0.31e 0.20 ± 0.33e 0.23 ± 0.32e 0.31 ± 0.32 0.49 ± 0.28 <0.001
Clinical pregnancy rate/ET (%) 25/77 (32.5) 19/72 (26.4) 14/38 (36.8) 8/15 (53.3) 124/275 (45.1) 0.02
Multiple pregnancy rate n (%) 6 (24) 6 (31.6) 5 (35.7) 1 (12.5) 29/124 (23.4) NS
Miscarriage rate/ET (%) 4/77 (5.2) 0/72 (0) 3/38 (7.9) 1/15 (6.7) 31/275 (11.3) NS
Live birth rate/ET (%) 21/77 (27.3) 19/72 (26.4) 11/38 (28.9) 7/15 (46.7) 93/275 (33.8) NS
ET = embryo transfer; MII = metaphase II; NS = not statistically signiﬁcant; PCOS = polycystic ovary syndrome.
aSigniﬁcantly different from phenotype A (the coexistence of hyperandrogenism (HA), chronic anovulation (AO), and polycystic ovaries).
bSigniﬁcantly different from phenotype B (HA and AO without the polycystic ovaries).
cSigniﬁcantly different from phenotype C (HA and polycystic ovaries).
dSigniﬁcantly different from phenotype D (AO and polycystic ovaries).
eSigniﬁcantly different from control group.
*All P-values for quantitative variables were determined by post-hoc analysis (Tukey).
507Predictive value of AMH for ART outcomes in different PCOS phenotypes.
Downloaded for Anonymous User (n/a) at Iran University of Medical Sciences from ClinicalKey.com by Elsevier on October 22, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
the presence of the PCOM and the LH/FSH ratio, CPR or LBR
was found.
A multivariable logistic regression analysis by backward
manner adjusted for women’s age and BMI was performed in
each PCOS phenotype separately (Table 4). The results dem-
onstrated that in PCOS phenotypes A and B, serum free tes-
tosterone concentration was the signiﬁcant predictor for CPR
and LBR (odds ratio [OR]: 0.4, conﬁdence interval [CI]: 0.3–
0.75; P = 0.01; OR: 0.5, CI: 0.4–0.9; P = 0.02, respectively).
This means that with every 1 pg/ml increase in serum free
testosterone concentration, CPR and LBR decrease 50–60% in
these patients. In addition, in women with PCOS phenotype
B, serum AMH concentration was the signiﬁcant predictor for
CPR and LBR (OR: 1.3, CI: 1.05–2.0; P = 0.01); in which for
every 1 ng/ml increase in serum AMH concentration, the
chance of clinical pregnancy and live birth increase 1.3 times.
The analysis in other PCOS phenotypes (C and D) showed that
only women’s age was important for prediction of CPR and
Table 3 Comparison of the main outcomes between two groups based on the observation of the PCO morphology by vaginal
ultrasonography.
Variables
Women with PCO
morphology (Phenotypes
A, C, and D) (n = 283)
Women without PCO
morphology (Phenotype
B) (n = 103)
P-value
AMH (ng/ml) (mean ± SD) 6.3 ± 2.8 5.1 ± 3.1 0.001
LH (IU/l) (mean ± SD) 8.1 ± 5.7 6.9 ± 4.8 0.05
LH/FSH ratio (mean ± SD) 1.5 ± 1.2 1.4 ± 1.0 NS
Freeze-all-embryos, n (%) 139 (49.1) 28 (27.2) 0.001
Clinical pregnancy rate/ET (%) 47/130 (36.2) 19/72 (26.4) NS
Live birth rate/ET (%) 39/130 (30) 19/72 (26.4) NS
AMH = anti-Müllerian hormone; ET = embryo transfer; PCO = polycystic ovarian; MII = metaphase II; NS = not statistically signiﬁcant.
Table 4 Multivariable logistic regression analysis by backward manner for determination of the predictive variables for clinical preg-
nancy and live birth rates in PCOS phenotypes and control (male factor) groups separately.
Variables
Predictive factors OR 95% CI P-value
PCOS Phenotype A
(n = 168)
Clinical pregnancy and
live birth
Serum free testosterone concentration 0.4 (0.3–0.75) 0.01
PCOS Phenotype B
(n = 103)
Clinical pregnancy and
live birth
Serum AMH concentration 1.3 (1.05–2.0) 0.01
Serum free testosterone concentration 0.5 (0.4–0.9) 0.02
PCOS Phenotype C
(n = 83)
Clinical pregnancy and
live birth
Women’s age 0.8 (0.6–−1.02) NS
PCOS Phenotype D
(n = 32)
Clinical pregnancy and
live birth
Women’s age 0.8 (0.6–1.07) NS
All PCOS women
(n = 386)
Clinical pregnancy Serum free testosterone concentration 0.6 (0.1–0.8) 0.02
Quality of transferred embryos
Good quality (A, B, and AB) Reference group
Fair quality (AC and BC) 0.47 (0.1–2.2) NS
Poor quality (C and CD) 0.34 (0.13–0.86) 0.02
Live birth Women’s age 0.9 (0.85–0.99) 0.04
Serum free testosterone concentration 0.5 (0.12–0.85) 0.01
Quality of transferred embryos
Good quality (A, B, and AB) Reference group
Fair quality (AC and BC) 0.3 (0.05–1.7) NS
Poor quality (C and CD) 0.4 (0.15–1.006) NS
Male factor
(control group)
(n = 350)
Clinical pregnancy Total number of retrieved oocytes 1.1 (1.01–1.2) 0.01
Quality of transferred embryos
Good quality (A, B, and AB) Reference group
Fair quality (AC and BC) 0.6 (0.3–1.1) 0.1
Poor quality (C and CD) 0.1 (0.02–0.38) 0.001
Live birth Total number of retrieved oocytes 1.06 (1.002–1.2) 0.04
Quality of transferred embryos
Good quality (A, B, and AB) Reference group
Fair quality (AC and BC) 0.5 (0.3–1.1) NS
Poor quality (C and CD) 0.1 (0.01–0.5) 0.009
AMH = anti-Müllerian hormone; CI = conﬁdence interval; OR = odds ratio; NS = not statistically signiﬁcant; PCO = polycystic ovarian.
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LBR; however, it did not reach a signiﬁcant level, probably
owing to low sample sizes in these two subgroups (Table 4).
Multivariable logistic regression analysis by backward
manner was performed in the PCOS group generally (n = 386).
The analysis showed that serum free testosterone concen-
tration and quality of transferred embryos were important pre-
dictors for CPR in PCOS women (P = 0.02). It also demonstrated
that women’s age and serum free testosterone concentra-
tion were the signiﬁcant predictors for LBR in these women
(P = 0.04 and P = 0.01, respectively). It means that in PCOS
women, with every one-year increase in women’s age the LBR
reduces by 10%. Also, with every 1 pg/ml increase in serum
free testosterone concentration, the LBR decreases by 50%.
The poor quality of transferred embryos was an important pre-
dictive variable for LBR; however, it did not reach a signiﬁ-
cant level (OR: 0.6, CI: 0.015–1.006) (Table 4).
In a similar way, the control group was evaluated by mul-
tivariable logistic regression analysis by backward manner to
ﬁnd the important predictive variables for CPR and LBR in this
population. Results revealed that the total number of re-
trieved oocytes and quality of transferred embryos were the
signiﬁcant predictors (P = 0.01 and P = 0.001, respectively).
It means that in women with male factor infertility, with every
increase of one in the total number of retrieved oocytes, the
chance of CPR increases 1.1 times. Also, the CPR and LBR in
women with poor quality of transferred embryos decreased
by 90% (Table 4).
The result of the backward multivariable logistic regres-
sion analysis in the whole study population after adjusting for
women’s age and BMI (n = 736) indicated that in addition to
the total number of retrieved oocytes and quality of trans-
ferred embryos, the PCOS phenotype A and B were signiﬁ-
cant predictive factors for CPR and LBR. This means that these
phenotypes were associated with a decreased CPR com-
pared with the male factor group (OR: 0.46, CI: 0.26–0.8, P
= 0.007 and OR: 0.34, CI: 0.18–0.62, P = 0.001, respec-
tively) (Table 5).
Discussion
The present study compared the IVF/ICSI outcomes in four
phenotypes of PCOS women and the control group and also
evaluated the predictive values of the LH/FSH ratio and AMH
concentration for CPR and LBR. The IVF/ICSI outcomes were
similar between the different PCOS phenotypes, but PCOS phe-
notypes A and B were associated with a 54% and 66% de-
crease in CPR compared with the control group, respectively.
It seems that a combination of hyperandrogenism and chronic
anovulation in patients with phenotypes A and B had a nega-
tive effect on CPR and LBR. Similarly, Palomba et al. (2010),
evaluated the effect of different PCOS phenotypes on ob-
stetric and neonatal outcomes and concluded that the risk of
adverse obstetric and neonatal outcomes in PCOS women
varies widely according to the different phenotypes and fea-
tures of PCOS. Their results showed that the risk of adverse
obstetric or neonatal outcomes was affected signiﬁcantly by
ovarian dysfunction and biochemical hyperandrogenism,
Table 5 Multivariable logistic regression analysis by backward manner for determination of the predictive variables for clinical preg-
nancy and live birth rates in whole study population, adjusted for women’s age and body mass index (n = 736).
Variables
Predictive factors Adjusted OR CI P-value
Clinical pregnancy Total number of retrieved oocytes 0.90 (0.81–0.97) 0.03
Quality of transferred embryos
Good quality (A, B, and AB) Reference group
Fair quality (AC and BC) 0.52 (0.33–0.84) 0.008
Poor quality (C and CD) 0.17 (0.1–0.4) 0.001
Study groups
PCOS phenotype A 0.46 (0.26–0.8) 0.007
PCOS phenotype B 0.34 (0.18–0.62) 0.001
PCOS phenotype C 0.6 (0.3–1.2) NS
PCOS phenotype D 2.0 (0.62–6.6) NS
Male factor (control group) Reference group
Live birth Total number of retrieved oocytes 0.9 (0.80–0.99) 0.04
Quality of transferred embryos
Good quality (A, B, and AB) Reference group
Fair quality (AC and BC) 0.57 (0.35–0.93) 0.02
Poor quality (C and CD) 0.15 (0.1–0.5) 0.003
Study groups
PCOS phenotype A 0.59 (0.33–1.06) NS
PCOS phenotype B 0.57 (0.31–1.03) NS
PCOS phenotype C 0.7 (0.33–1.5) NS
PCOS phenotype D 2.3 (0.75–7.5) NS
Male factor (control group) Reference group
CI = conﬁdence interval; NS = not statistically signiﬁcant; OR = odds ratio; Phenotype A = the coexistence of hyperandrogenism (HA), chronic
anovulation (AO), and polycystic ovaries); Phenotype B = the coexistence of HA and AO without the polycystic ovaries; Phenotype C = the
coexistence of HA and polycystic ovaries; Phenotype D = the coexistence of AO and polycystic ovaries; PCOS = polycystic ovarian syndrome.
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whereas no signiﬁcant effect was detected for clinical
hyperandrogenism and the PCOM (Palomba et al., 2010).
Results from this study demonstrated a relationship
between the serum AMH concentration and PCOS pheno-
types, that the phenotype B women had signiﬁcantly lower
concentrations of AMH than the women with phenotypes A
and C. These ﬁndings are in agreement with previous studies
reporting that the serum AMH concentration is allied to the
severity of PCOS (Tal et al., 2014). Likewise, Parahuleva et al.
(2014), reported some differences in the values of AMH in the
four main PCOS phenotypes and found direct correlations
between the concentrations of AMH and other hormonal pa-
rameters. Based on the recent studies (Casadei et al., 2013;
Eilertsen et al., 2012; Iliodromiti et al., 2013) highlighting dif-
ferences in serum AMH concentrations in various pheno-
typic expressions of PCOS, the AMH concentration may serve
as a reliable tool for the prediction, diagnosis, monitoring and
categorization of the severity of this syndrome. In this regard,
Dewailly et al. (2011), concluded that a serum AMH >5 ng/
ml seems to bemore sensitive and speciﬁc than follicle number
in the diagnosis of PCOM; therefore it should be considered
in current diagnostic classiﬁcation for PCOS. Along the same
lines, Casadei et al. (2013), suggested that the measure-
ment of AMH may be considered as the main diagnostic cri-
terion for the diagnosis of PCOS when either hyperandrogenism
or anovulation is missing and/or when no reliable AFC can be
measured.
This study also found that AMH concentration was predic-
tive for CPR and LBR only in PCOS women with phenotype B,
whereas it was not predictive in other PCOS phenotypes. In
this regard, Tal et al. (2014), showed that PCOS women with
ultra-high AMH concentrations had signiﬁcantly more good-
quality embryos and increased CPR. Conversely, Xi et al.
(2012), reported that CPR was lower in PCOS women with high
concentrations of AMH, as the clinical pregnancy rates were
65%, 66.7% and 45.9%, in <25%, 25–75% and >75% percen-
tiles of the serum AMH groups, respectively. Elsewhere,
Sahmay et al. (2013), demonstrated that the mean AMH con-
centrations were not signiﬁcantly different between preg-
nant and non-pregnant PCOS women. In their study, CPR
increased in parallel with a rise in the AMH percentiles, al-
though this relationship was insigniﬁcant. Only a few studies
have evaluated the predictive value of serum AMH for preg-
nancy in a PCOS-only group (Sahmay et al., 2013; Tal et al.,
2014; Xi et al., 2012). The conﬂicting results of these studies
can be due to the differences in measurement methods and
categorization of AMH concentrations as well as the pres-
ence of various PCOS phenotypes in different races (Sahmay
et al., 2013). It seems that more studies are necessary to draw
a deﬁnitive conclusion regarding the predictive value of serum
AMH for ART outcomes in PCOS-only patients.
Results from this study showed that in women with male
factor infertility, total number of retrieved oocytes and quality
of transferred embryos were signiﬁcant predictors for CPR and
LBR, whereas serum AMH concentration was not a signiﬁ-
cant predictor. Previous studies reported that AMH is a sig-
niﬁcant predictor for CPR (Elgindy et al., 2008; Hazout et al.,
2004; Lekamge et al., 2007; Wu et al., 2009), while some
others could not ﬁnd such results (Choi et al., 2011; Penarrubia
et al., 2005; Smeenk et al., 2007). Two recent prospective
studies reported the predictive value of AMH for LBR (Lee
et al., 2009; Nelson et al., 2007). Nelson et al. (2007), reported
that LBR increased with increasing AMH concentrations; al-
though this is signiﬁcant only for patients with basal AMH con-
centrations <7.8 pmol/l and in patients with AMH above this
value, there was no relationship between live birth and AMH.
However, in their study, after multivariable regression analy-
sis, they found that oocyte yield was the only signiﬁcant pre-
dictive variable for live birth. Elsewhere, Wang et al. (2010),
concluded that AMH concentration is an important factor to
predict IVF pregnancy rates for women aged between 34 and
41 years; however, it has limited predictive value in younger
and older women. In a recent study, Khader et al. (2013), con-
ﬁrmed the external validity of a particular nomogram to de-
termine the probability of live births by age and AMH; however,
Mutlu et al. (2013), in a recent prospective study, reported
that female age is the only predictor for LBR in IVF cycles.
Similarly, Broer et al. (2013), in a recent meta-analysis re-
ported that the best single predictor for ongoing pregnancy
was women’s age. According to the conﬂicting results, it seems
that the role of infertility aetiology must be important in evalu-
ating the predictive values of different variables for ART out-
comes. Presumably, in different infertility subgroups, the
variables affecting the probability of pregnancy and live birth
have different predictive values.
This study’s results indicate that high basal LH concen-
trations (≥10 IU/l) and high LH/FSH ratios (≥2.5) had no nega-
tive effect on CPR and LBR in IVF/ICSI cycles in PCOS women.
In this regard, Geng et al. (2013), evaluated 134 PCOS women
retrospectively and concluded that a basal LH concentra-
tion >10 IU/l or a high LH/FSH ratio (≥2) did not produce an
obvious deleterious impact on the clinical results of IVF-
embryo transfer in their PCOS women, who were on oral con-
traceptives for pretreatment before the long GnRH-agonist
protocol. On the other hand, Wiser et al. (2013), reported that
possibly the high basal LH concentration impaired ovarian
folliculogenesis, oocyte quality and consequently the preg-
nancy rate in in-vitro maturation cycles. The fact that the
ovarian stimulation protocol in our study population was a stan-
dard agonist or antagonist seems to conﬁrm the ﬁnding of the
study by Tarlatzis et al. (1995), who remarked that using the
GnRH agonist or antagonist in the standard protocol over-
came the possible negative effect of elevated basal LH on fol-
licular and oocyte development.
The limitation of this study was the absence of a uniform
COH protocol in all the patients. Nonetheless, the effect of
the COH protocol on the main outcomes was evaluated using
a multivariable regression test that demonstrated that the COH
protocol had no impact on CPR and LBR.
In conclusion, this study found that in PCOS women a com-
bination of hyperandrogenism and chronic anovulation as in
phenotypes A and B were associated with lower CPR and LBR
compared with the control group. The study suggested that
the serum AMH concentration was related to PCOM but is not
predictive for CPR and LBR. However, further prospective
studies are needed to conﬁrm or refute these ﬁndings.
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